Last updated: April 23, 2026
Who supplies docetaxel API and how is the supply chain structured?
Docetaxel is supplied into the pharmaceutical market through three layers:
1) Docetaxel active pharmaceutical ingredient (API) manufacturers
2) Intermediates and key starting materials suppliers that support API synthesis
3) Contract manufacturers (CMOs) that formulate and fill docetaxel drug product (typically vials or infusion concentrate)
Procurement and risk work typically treat these as separate vendor qualification tracks because supply continuity, change control, and quality systems differ by layer.
Which companies are active docetaxel API suppliers?
The docetaxel API supplier base is concentrated among established generics and oncology API players with multiple approvals, audits, and documentation depth for regulated markets. Active suppliers include:
- Jiangsu Hengrui Medicine Co., Ltd. (China)
- Cipla Ltd. (India)
- Macleods Pharmaceuticals (India)
- Accord Healthcare (India)
- EirGen Pharma Ltd. (Ireland) / Accord-affiliated oncology supply chains
- Hetero Labs (India)
- Sichuan Kelun Pharmaceutical Co., Ltd. (China)
Procurement implication: vendor selection should be tied to (i) dossier status for target jurisdictions, (ii) batch release control access, and (iii) documented comparability for particle size/solubility control because docetaxel is formulation-sensitive.
Who supplies docetaxel drug product (vials/infusion concentrate) via CMOs?
Docetaxel drug product supply is commonly handled by companies with oncology sterile capabilities and validated aseptic manufacturing. A typical supplier set includes:
- Dr. Reddy’s Laboratories (India)
- Sandoz (India/Germany network depending on market)
- Teva Pharmaceuticals (global manufacturing network)
- Accord Healthcare (global market-facing sites)
- Cipla (global supply network)
- Hospira legacy network assets (market-specific)
Procurement implication: for drug product, qualification should focus on sterile aseptic controls, hold-time studies, and validated container-closure systems for docetaxel concentrates.
Which intermediates and key starting materials matter for docetaxel sourcing?
Docetaxel synthesis depends on specialized intermediates. Common procurement categories (used to map vendor continuity and substitution risk) include:
- Taxane core intermediates (including semisynthetic routes from taxane precursors)
- Side-chain and stereochemical building blocks
- Solvent and reagent systems under cGMP controls
- Crystallization control agents and polymorph management inputs (where suppliers support defined solid-state specs)
Procurement implication: even when the API supplier remains fixed, intermediate sourcing changes can trigger impurity profile shifts and regulatory comparability updates.
What vendor due-diligence points should be applied to docetaxel suppliers?
Docetaxel is a high-control oncology product. Supplier qualification should apply a consistent checklist:
Regulatory and quality documentation
- DMF/CEP status mapped to each target market
- Latest audit outcome and remediation history (last 2 to 3 years)
- Impurity profile controls aligned to the target regulatory pathway
- Batch release CoA access with defined acceptance ranges
Manufacturing and supply continuity
- Evidence of capacity headroom for campaign length and requalification intervals
- Cold-chain or special handling needs (docetaxel is generally not cold-chain, but handling and viscosity/particulate management in formulation matter)
- Validated change control for synthesis steps affecting critical quality attributes
Formulation sensitivity (drug product layer)
- Particle size or solubility specifications (as supported by the API spec and drug product acceptance criteria)
- Aseptic processing controls and sterility assurance approach
- Container-closure compatibility for infusion concentrate/vial presentations
Where are docetaxel suppliers concentrated by geography?
Supplier concentration typically clusters into:
- India: strong oncology generics and sterile CMOs
- China: large-volume oncology API and intermediates with multi-dossier coverage
- Europe/US: drug product and specialty distribution networks, plus CMO activity for oncology sterile fills
Procurement implication: diversification by geography often reduces single-country risk but increases the need for cross-vendor comparability management.
How to use the supplier list in a procurement and investment workflow
For business decisions, split sourcing into three workstreams and assign ownership:
1) API vendor shortlist: qualify based on dossier status, impurity acceptance, and solid-state specs.
2) Intermediate risk audit: verify that intermediate suppliers are either fixed or contractually controlled with notification and comparability pathways.
3) Drug product CMO selection: qualify on aseptic capability, fill-finish experience with oncology concentrates, and change-control history.
Key Takeaways
- Docetaxel supply typically runs through API producers, intermediate suppliers, and sterile drug product CMOs; each layer has different continuity and compliance risks.
- Active docetaxel API sourcing is concentrated among major oncology API and generics players including Jiangsu Hengrui, Cipla, Macleods, Accord, Hetero Labs, and Sichuan Kelun (market coverage varies by jurisdiction and dossier status).
- Docetaxel drug product manufacturing is generally handled by sterile oncology-capable networks including Dr. Reddy’s, Sandoz, Teva, Accord, and Cipla (site and presentation vary by country).
- Vendor qualification should be driven by dossier and impurity profile alignment, not just supply availability, due to docetaxel’s formulation sensitivity.
FAQs
1) What are the main categories of docetaxel suppliers?
API manufacturers, intermediate suppliers (taxane-related building blocks and stereochemical intermediates), and sterile drug product CMOs for vial and infusion concentrate manufacture.
2) Why is docetaxel harder to source than many other oncology drugs?
Docetaxel is formulation- and solid-state sensitive; impurity profiles and solid-state attributes can change with synthesis routes and intermediate sourcing.
3) Should procurement prioritize API or drug product vendors?
For launch or supply assurance, procurement should parallel-track both: API continuity affects downstream production reliability, and drug product manufacturing quality controls drive patient-ready product performance.
4) Which geographies have the deepest docetaxel supplier ecosystems?
India and China dominate the API/intermediate and generics/CMO ecosystems; Europe and the US add significant drug product and regulated market distribution activity.
5) What due-diligence artifacts should be requested from docetaxel suppliers?
DMF/CEP status mapping, latest audit outcomes, batch CoAs with acceptance ranges, and change-control/comparability documentation affecting impurities and solid-state specs.
References
[1] FDA. (2024). Drug Shortages. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/drugshortages/
[2] European Medicines Agency. (2024). EPAR and product information for docetaxel-containing medicines. https://www.ema.europa.eu/
[3] World Health Organization. (2024). WHO Model Lists of Essential Medicines and related documentation. https://www.who.int/
[4] PubChem. (2024). Docetaxel: compound information. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/
[5] United States Pharmacopeia (USP). (2024). USP monographs and quality standards related to docetaxel products. https://www.uspnf.com/
